Todd Girolamo Increases Stake in ProKidney Corp.
ProKidney's Chief Legal Officer, Todd Girolamo, bought 163,857 shares on June 12, 2026.
Key Points
- Todd Girolamo, ProKidney's Chief Legal Officer, purchased 163,857 shares on June 12, 2026.
- ProKidney Corp. (NASDAQ: PROK) is trading at $1.67 with a market cap of $342.7 million.
- Analysts from HC Wainwright & Co. reiterated a 'buy' rating with a $12 target on May 18, 2026.
Todd Girolamo, the Chief Legal Officer of ProKidney Corp., has increased his stake in the company by purchasing 163,857 shares. This transaction took place on June 12, 2026, as ProKidney shares traded at $1.67 on the Nasdaq Capital Market.
Insider Buying and Selling at ProKidney Corp.
Todd Girolamo made a significant purchase of 163,857 shares on June 12, 2026. This move was not part of a pre-arranged trading plan, indicating his direct interest in increasing his holdings. Other insiders, including William Doyle, Uma Sinha, and Alan Lotvin, also bought 135,000 shares each on May 28, 2026.
ProKidney Corp. Stock Snapshot
Shares of NasdaqCM:PROK are currently trading at $1.67. ProKidney Corp. has a market cap of approximately $342.7 million and a beta of 1.7, indicating some volatility compared to the market. The stock's 52-week range is between $0.54 and $7.13, with a 50-day moving average of $1.83 and a 200-day moving average of $2.25. The company maintains a strong liquidity position with a current ratio of 9.06 and a quick ratio of 8.72.
Analysts Set New Price Targets
On May 18, 2026, HC Wainwright & Co. reiterated its 'buy' rating for ProKidney with a price target of $12. The consensus among analysts is a 'buy' recommendation, with a mean target price of $6.25 based on six analyst opinions.
About ProKidney Corp.
ProKidney Corp. is a biotechnology company based in Winston-Salem, North Carolina. Founded in 2015, it focuses on developing cell therapies for chronic kidney diseases. The company is advancing its lead product, rilparencel, through Phase III clinical trials for conditions such as advanced chronic kidney disease and type 2 diabetes. ProKidney is also working on several cryopreserved versions of rilparencel in various stages of clinical trials.
Bottom Line
Insider buying activity by Todd Girolamo highlights his confidence in ProKidney Corp.'s prospects. Investors often track such insider transactions for potential insights into company health. This information is based on filings and may not reflect current holdings, as insider transactions are reported after the fact.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.